IPO Issue Details
Issue Price / Price Band₹896 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size16 Shares per Lot
Total Issue Size45,94,875 shares (aggregating up to ₹411.49 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenWed, 20 Jul 2016
Subscription CloseFri, 22 Jul 2016
Anchor AllotmentTue, 19 Jul 2016
Basis of AllotmentThu, 28 Jul 2016
Initiation of RefundsFri, 29 Jul 2016
Credit of Shares to DematFri, 29 Jul 2016
Listing DateMon, 01 Aug 2016
UPI Mandate Deadline2016-07-22
Application & Investment Details
Retail — Min (1 Lots)₹14,336 — 16 shares
Retail — Max (13 Lots)₹186,368 (13 Lots)
HNI — Min (14 Lots)₹2,00,704 — 224 shares
Pre-IPO Promoter Holding2,17,65,600 shares
Post-IPO Promoter Holding2,23,26,005 shares
Fresh Issue Shares5,60,405 shares (aggregating up to ₹50.19 Cr)
Offer for Sale Shares40,34,470 shares of ₹10 (aggregating up to ₹361.30 Cr)
About Advanced Enzyme Technologies Ltd.
Incorporated in 1989, Advanced Enzyme Technologies Ltd is an India based company engaged in research, development, manufacturing and marketing of Healthcare, Nutrition and Bio-Processing products. Information in this paragraph is copied from chittorgarh.com.Company produces over 400 proprietary products developed from 60 enzymes. Advanced Enzyme operate in two primary business verticals namely Healthcare & Nutrition (human and animal) and Bio-Processing (food and non-food).Company has 13 patents registered in its name and applications for registration of 4 patents are pending.Advanced Enzyme is among top 15 companies in enzyme sales in the world and 2nd largest in India. Company has over 20 years of fermentation experience in the production of enzymes. Company offer these products to its more than 700 global customers across 50 countries around the world. Content in this paragraph is copied from chittorgarh.com.Advanced Enzyme's R&D team consists of over 55 scientists, microbiologists, engineers, food technologists and biotechnologists. Company have four R&D facilities, of which two are located at Thane, and one each at Sinnar and Chino, California.Competitive strengths of the company:1. Integrated Company with presence across the Enzyme Value Chain2. Strong R&D, enzyme development and manufacturing capabilities3. Specialized Business Model with high entry barriers4. Diversified Product Portfolio and Wide Customer Base, served by a Strong Sales, Marketing and Distribution network5. Experienced Promoters and Strong Management Team6. Financial stability and stable cash flows
Objects of the Issue
Advanced Enzyme Technologies Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Investment in Advanced Enzymes USA, the wholly owned subsidiary for repayment/pre-payment of certain loans availed by Advanced Enzymes USA
40.00
2
2 General corporate purpose
7.20
Shareholding & Lock-in
Pre-IPO Promoter Holding
2,17,65,600 shares
Post-IPO Promoter Holding
2,23,26,005 shares